The year 2017 was a very good year for U.S. Stocks. The S&P 500 Index had a yearly gain of 18.87%. The major market indexes had 71 new high points for the year.
If you pay a fee or commission to a broker or money manager, you need to ask one very important question. You should ask: ” How much did my investments increase in 2017? ” If your assets invested did not increase by 18.87% or more, then you are paying someone to underperform the market with your money ! About 70% of all mutual funds underperform the S&P 500 Index !
Looking at the data generated in the U.S. stock market in 2017, there were some stocks that greatly outperformed the S&P index and there were some stocks that greatly underperformed the S&P index.
I have a list of the top ten U.S. Stocks that increased in market value in 2017. I list the stock by name first, then I list the ticker symbol, and then I list the stock’s increase in price as a percentage gain. They are as follows: 1) Sangamo Therapeutics, SGMO, 450.0%. 2) Straight Path Communications, STRP, 401.8%, 3) Nektar Therapeutics, NKTR, 376.8%, 4) Immunomedics, IMMU, 337.5%, 5) Foundation Medicine, FMI, 286.8%, 6) Lending Tree, TREE, 284.7%, 7) Sage Therapeutics, SAGE, 277.3%, 8) ImmunoGen, IMGN, 221.2%, 9) Apollo Medical, AMEH, 220%, and 10) Puma Biotechnology, PBYI, 216.8%.
Of course, I could list the bottom ten U.S. Stocks that decreased in market value in 2017. While I will not list them, be aware that they exist. Also remember that there is no computer program anywhere in the world that can predict with 100% accuracy what stocks will gain or lose in 2018!
I plan to publish my basic projections for the U.S. Markets in 2018 in another post that will soon follow. For now, I can safely predict that some stocks will gain in value in 2018 and some stocks will lose in value in 2018. You can count on it.
R. Van Conoley